Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.

Welby JP, Kaptzan T, Wohl A, Peterson TE, Raghunathan A, Brown DA, Gupta SK, Zhang L, Daniels DJ.

Front Oncol. 2019 Feb 27;9:92. doi: 10.3389/fonc.2019.00092. eCollection 2019.

2.

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM.

Oncotarget. 2018 Dec 14;9(98):37112-37124. doi: 10.18632/oncotarget.26430. eCollection 2018 Dec 14. Erratum in: Oncotarget. 2019 Apr 12;10(28):2788.

3.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A.

Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27.

4.

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.

Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K.

Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27.

PMID:
28263309
5.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

6.

Genomic Insights into Diffuse Intrinsic Pontine Glioma.

Lapin DH, Tsoli M, Ziegler DS.

Front Oncol. 2017 Mar 28;7:57. doi: 10.3389/fonc.2017.00057. eCollection 2017. Review.

7.

International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Tsoli M, Shen H, Mayoh C, Franshaw L, Ehteda A, Upton D, Carvalho D, Vinci M, Meel MH, van Vuurden D, Plessier A, Castel D, Drissi R, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Francis S, Ludlow LEA, Carai A, Mastronuzzi A, Liu B, Hansford J, Gottardo N, Hassall T, Kirby M, Fouladi M, Hawkins C, Monje M, Grill J, Jones C, Hulleman E, Ziegler DS.

J Neurooncol. 2019 Jan;141(2):253-263. doi: 10.1007/s11060-018-03038-2. Epub 2018 Nov 16. Erratum in: J Neurooncol. 2018 Nov 27;:.

PMID:
30446898
8.

Detection of H3K27M mutation in cases of brain stem subependymoma.

Yao K, Duan Z, Wang Y, Zhang M, Fan T, Wu B, Qi X.

Hum Pathol. 2019 Feb;84:262-269. doi: 10.1016/j.humpath.2018.10.011. Epub 2018 Oct 30.

PMID:
30389438
9.

Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.

Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA.

Acta Neuropathol Commun. 2018 Nov 5;6(1):117. doi: 10.1186/s40478-018-0614-1.

10.

Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.

Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Santi M, Cruz CR, Packer RJ, Almira-Suarez MI, Hwang EI, Nazarian J.

J Neuropathol Exp Neurol. 2019 May 1;78(5):380-388. doi: 10.1093/jnen/nlz021.

11.

Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

Cohen KJ, Jabado N, Grill J.

Neuro Oncol. 2017 Aug 1;19(8):1025-1034. doi: 10.1093/neuonc/nox021. Review.

12.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
13.

New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis.

Plessier A, Le Dret L, Varlet P, Beccaria K, Lacombe J, Mériaux S, Geffroy F, Fiette L, Flamant P, Chrétien F, Blauwblomme T, Puget S, Grill J, Debily MA, Castel D.

Oncotarget. 2017 Feb 2;8(32):52543-52559. doi: 10.18632/oncotarget.15002. eCollection 2017 Aug 8.

14.

H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.

Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ.

Acta Neuropathol. 2019 Apr;137(4):637-655. doi: 10.1007/s00401-019-01975-4. Epub 2019 Feb 15. Erratum in: Acta Neuropathol. 2019 Apr 11;:.

PMID:
30770999
15.

Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges.

Himes BT, Zhang L, Daniels DJ.

Front Oncol. 2019 Feb 8;9:31. doi: 10.3389/fonc.2019.00031. eCollection 2019. Review.

16.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
17.

Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.

Lu VM, Alvi MA, McDonald KL, Daniels DJ.

J Neurosurg Pediatr. 2018 Nov 30;23(3):308-316. doi: 10.3171/2018.9.PEDS18419. Review.

PMID:
30544362
18.

Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.

Xu C, Liu X, Geng Y, Bai Q, Pan C, Sun Y, Chen X, Yu H, Wu Y, Zhang P, Wu W, Wang Y, Wu Z, Zhang J, Wang Z, Yang R, Lewis J, Bigner D, Zhao F, He Y, Yan H, Shen Q, Zhang L.

Oncotarget. 2017 Jul 28;8(44):76644-76655. doi: 10.18632/oncotarget.19656. eCollection 2017 Sep 29.

19.

Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.

Stafford JM, Lee CH, Voigt P, Descostes N, Saldaña-Meyer R, Yu JR, Leroy G, Oksuz O, Chapman JR, Suarez F, Modrek AS, Bayin NS, Placantonakis DG, Karajannis MA, Snuderl M, Ueberheide B, Reinberg D.

Sci Adv. 2018 Oct 31;4(10):eaau5935. doi: 10.1126/sciadv.aau5935. eCollection 2018 Oct.

20.

Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?

Lobon-Iglesias MJ, Giraud G, Castel D, Philippe C, Debily MA, Briandet C, Fouyssac F, de Carli E, Dufour C, Valteau-Couanet D, Sainte-Rose C, Blauwblomme T, Beccaria K, Zerah M, Puget S, Calmon R, Boddaert N, Bolle S, Varlet P, Grill J.

J Neurooncol. 2018 Mar;137(1):111-118. doi: 10.1007/s11060-017-2702-7. Epub 2017 Dec 2.

PMID:
29198053

Supplemental Content

Support Center